Phase III Factive data

Oscient (OSCI) said its Factive gemifloxacin met the primary endpoints in two

Read the full 127 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE